news
The lead candidate, ADG2, was able to neutralise SARS-CoV and…
26 January 2021 | By Hannah Balfour (Drug Target Review)
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.